SuperworthAdaptive Biotechnologies ADPT
- Market cap
- $4.1B
- PE
- n/m
- a loss over the last year
- Forward PE
- n/m
- not a meaningful number
- Price to sales
- 13.2×
- EV/EBIT
- n/m
- a loss over the last year
- Revenue, 12 months
- $308.1M
- +50% on a year ago
- Net margin
- −20.7%
- Free cash flow yield
- −0.6%
Adaptive Biotechnologies trades at 13.2× sales. Its trailing earnings are negative, so it has no PE. Revenue was $308.1M over the last twelve months, up 50% on a year earlier with a −21% net margin.
Charts
Financials
| Income statement | Q3 FY23 | Q4 FY23 | Q1 FY24 | Q2 FY24 | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $37.9M−21% | $45.8M−17% | $41.9M+11% | $43.2M−12% | $46.4M+23% | $47.5M+4% | $52.4M+25% | $58.9M+36% | $94M+102% | $71.7M+51% | $70.9M+35% | $71.6M+22% | |
| Cost of revenue | $19.3M+30% | $19.6M+18% | $18.1M−3% | $19.3M+8% | $16.7M−14% | $18M−8% | $17M−6% | $18M−7% | $18.2M+9% | $18.2M+1% | $18.7M+10% | $20.2M+12% |
| Gross profit | $18.6M−44% | $26.2M−32% | $23.8M+26% | $23.9M−23% | $29.8M+60% | $29.4M+12% | $35.5M+49% | $40.9M+71% | $75.8M+155% | $53.5M+82% | $52.2M+47% | $51.4M+26% |
| R&D | $28.5M−20% | $28.7M−8% | $30.2M−7% | $25.4M−21% | $24.2M−15% | $23.2M−19% | $24.2M−20% | $24.1M−5% | $23.7M−2% | $21.8M−6% | $23.6M−2% | $19.2M−21% |
| SG&A | $40.6M−4% | $42.6M−8% | $41.9M−3% | $38.2M−17% | $37.8M−7% | $39.6M−7% | $40.4M−4% | $41.4M+8% | $41.4M+10% | $44M+11% | $47.3M+17% | $47.6M+15% |
| −$51M+12% | −$71.1M+81% | −$48.8M−15% | −$47.3M−1% | −$32.6M−36% | −$33.8M−52% | −$29.6M−39% | −$25M−47% | $10.3M | −$12.8M−62% | −$19.2M−35% | −$15.8M−37% | |
| Interest expense | $3.7M+459% | $3M−16% | $3M−15% | $2.7M−25% | $2.9M−20% | $3M−2% | $2.9M−3% | $2.9M+9% | $3M+1% | $3M+0% | $2.9M−1% | $2.7M−9% |
| n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | |
| Net income | −$50.3M+11% | −$69.4M+73% | −$47.5M−18% | −$46.2M−3% | −$32.1M−36% | −$33.7M−52% | −$29.9M−37% | −$25.6M−45% | $9.5M | −$13.6M−60% | −$20M−33% | −$39.8M+55% |
| −$0.35+9% | −$0.48+71% | −$0.33−18% | −$0.31−6% | −$0.22−37% | −$0.23−52% | −$0.20−39% | −$0.17−45% | $0.06 | −$0.09−61% | −$0.13−35% | −$0.25+47% | |
| 144.7M+1% | 144.9M+1% | 145.8M+2% | 147.4M+2% | 147.5M+2% | 147.7M+2% | 149.2M+2% | 152.1M+3% | 163.2M+11% | 153.1M+4% | 155.5M+4% | 159.9M+5% |
Revenue: Q1 FY18 and Q1 FY19: 6 months less the 3 months printed beside them.
Cost of revenue: Q1 FY18 and Q1 FY19: 6 months less the 3 months printed beside them.
Gross profit: Q1 FY18 and Q1 FY19: 6 months less the 3 months printed beside them. 32 periods, Q2 FY18 to Q2 FY26: not printed by the filing, worked out from its own lines.
R&D: Q1 FY18 and Q1 FY19: 6 months less the 3 months printed beside them.
SG&A: Q1 FY18 and Q1 FY19: 6 months less the 3 months printed beside them.
Operating income: Q1 FY18 and Q1 FY19: 6 months less the 3 months printed beside them.
Net income: Q1 FY18 and Q1 FY19: 6 months less the 3 months printed beside them.
EPS, diluted: 10 periods, Q1 FY18 to Q4 FY25: quarter's net income to common over its shares, to the cent.
Diluted shares: Q1 FY18: share-days: the 6-month average less the second quarter's. 8 periods, Q4 FY18 to Q4 FY25: a loss quarter: its basic count, share-days: the 12-month average less the 9-month, weighted by days.
From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.
Peers
Companies in Biotechnology nearest Adaptive Biotechnologies' size, closest first.
| Company | Market cap | PE | Its 10y median PE | Fwd PE | P/S | Revenue growth | Net margin |
|---|---|---|---|---|---|---|---|
| ADPTAdaptive Biotechnologies | $4.1B | n/m | n/a | n/m | 13.2× | +50% | −20.7% |
| ADMAAdma Biologics | $2.4B | 15.3× | 21.5× | n/m | 4.7× | +8% | 33.0% |
| VCELVericel | $2.2B | 92.5× | 158× | n/m | 7.1× | +23% | 7.9% |
| KRYSKrystal Biotech | $9.2B | 39.0× | 42.7× | n/m | 20.9× | +23% | 54.8% |
| RGENRepligen | $10B | 242× | 120× | n/m | 12.7× | +16% | 5.3% |
| TECHBIO-TECHNE | $11.4B | 63.1× | 61.6× | n/m | 9.4× | −0% | 15.0% |
| HALOHalozyme Therapeutics | $14.3B | 37.5× | 21.3× | n/m | 8.6× | +41% | 24.9% |
| NBIXNeurocrine Biosciences | $14.5B | 20.9× | 42.8× | n/m | 4.3× | +34% | 20.9% |
| EXELExelixis | $16B | 20.3× | 22.8× | n/m | 6.6× | +9% | 35.3% |
| MGTXMeiraGTx | $884.6M | 13.0× | 18.0× | n/m | 2.2× | n/m | 19.9% |
| INCYIncyte | $23.5B | 14.7× | 36.9× | 49.5× | 4.0× | +27% | 27.7% |
| Peer median | $10.7B | 29.2× | 39.8× | 49.5× | 6.8× | +23% | 22.9% |
Investors who own it
Investors we follow who held Adaptive Biotechnologies at the end of Jun 30, 2026, from their 13F filings.
- Andreas HalvorsenViking Global Investors1.8% of portfolio
- Cathie WoodARK Investment Management0.3% of portfoliotrimmed
- Polen CapitalPolen Capital0.0% of portfoliotrimmed
More on Adaptive Biotechnologies
Each number over time
- PE ratio
- Price to sales ratio
- Price to book ratio
- Market cap
- Revenue
- EPS
- Free cash flow
- Profit margin
- Shares outstanding
Its groups
About
- Industry
- Biotechnology
- Sector
- Healthcare
Valuation data, not investment advice. Prices as of .